# US 2024/0296902 A1 · Methods, Systems and Computer Programs for Assessing CHD Risk Using Adjusted HDL Particle Number Measurements

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0296902 A1
- Document ID: US20240296902A1
- Status: Published application
- Kind: A1
- Application number: 18/598,979
- Filed: 2024-03-07
- Published: 2024-09-05
- Earliest claimed: 2006-05-10
- Assignees: LipoScience, Inc.
- Applicants: Liposcience, Inc.
- Inventors: James D. Otvos
- Web page: https://patentgrep.com/patent/US20240296902A1

## CPC

- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G01N 15/0656: {using electric, e.g. electrostatic methods or magnetic methods (by investigating individual particles G01N15/1031, G01N15/12)}
- G01N 24/08: by using nuclear magnetic resonance (G01N24/12 takes precedence)
- G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/00: ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/50: for simulation or modelling of medical disorders
- G01N 15/01: specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N15/05)
- G01N 2800/323: Arteriosclerosis, Stenosis
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.

## Claims

### Claim 1

A method of determining a subject's risk of having and/or developing CHD, comprising:
obtaining concentration measurements of small and large HDL subclass particles in a biosample;
programmatically adjusting the obtained value of the small HDL subclass particle concentration measurement, the large HDL subclass particle concentration measurement, or the concentration measurements of both small and large HDL subclass particles; and
determining a subject's risk of having and/or developing CHD based on the adjusted HDL subclass particle concentration measurement.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the adjusting step is based on a predetermined mathematical model that predicts the subject's cardiovascular risk, and wherein the mathematical model comprises a first weighting factor for the obtained concentration measurement of small HDL particles and a second different weighting factor for the obtained concentration measurement of large HDL particles.

### Claim 5 (depends on 4)

The method of claim 4, wherein the first and second weighting factors are multiplied to the respective small and large HDL subclass particle measurements and the results are summed to provide a weighted HDL particle risk factor number.

### Claim 6 (depends on 1)

The method of claim 1, wherein the adjusting step is carried out so that the large HDL particle concentration measurement is increased relative to the small HDL particle concentration measurement.

### Claim 7 (depends on 1)

The method of claim 1, wherein the obtaining step further comprises obtaining a concentration measurement of medium HDL subclass particles, and wherein the adjusting step is carried out so that the values of the medium HDL particle concentration measurement and the large HDL particle concentration measurement are increased relative to the value of the small HDL particle concentration measurement.

### Claim 8 (depends on 1)

The method of claim 1, wherein the obtaining step further comprises substantially concurrently obtaining NMR derived concentration measurements of small HDL subclass particles and large HDL subclass particles.

### Claim at position 8

9-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the obtaining step further comprises: deconvolving at least one NMR spectroscopic signal of the biosample to calculate the small and large HDL particle subclass concentration measurements.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method of claim 13, wherein the obtaining step further comprises calculating medium HDL particle subclass concentration measurements, and wherein the adjusting step further comprises applying at least one weighting factor to increase the values of the medium HDL particle concentration measurement and the large HDL particle concentration measurement relative to the small HDL subclass particle concentration measurement.

### Claim 16

(canceled)

### Claim 17

A computer program product for adjusting measured in vitro concentrations of HDL particles to assess CHD risk, the computer program product comprising:
a computer readable storage medium having computer readable program code embodied in said medium, said computer readable program code comprising:
computer readable program code that adjusts measured in vitro concentrations of small HDL subclass particles, large HDL subclass particles, or the concentration measurements of both small and large HDL subclass particles to generate an HDL risk number to reflect a subject's risk of having or developing CHD.

### Claim at position 14

18-27. (canceled)

### Claim 28

A system for obtaining data regarding lipoprotein constituents in a subject, comprising:
an NMR spectrometer for acquiring at least one NMR spectrum of an in vitro biosample; and
a controller in communication with the NMR spectrometer, the controller comprising a computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
computer program code for determining concentrations of small and large HDL subclass particles in the biosample undergoing analysis; and
computer program code for adjusting of the determined concentration of small subclass particles, large HDL subclass particles or the determined concentration of both small and large HDL subclass particles to determine a risk of the subject developing or having CHD.

### Claim 29 (depends on 28)

The system of claim 28, wherein the at least one NMR spectrum comprises a composite spectrum, the controller further comprising computer program code defining a plurality of individual NMR constituent spectra, each associated with a selected reference lipoprotein constituent signal lineshape, each constituent spectrum having associated spectra that contribute to the composite NMR spectrum of the biosample.

### Claim 30 (depends on 28)

The system of claim 28, wherein the computer program code for adjusting the determined concentrations includes computer program code for increasing the determined concentration of large HDL subclass particles relative to the determined concentration of small HDL subclass particles.

### Claim at position 18

31-42. (canceled)
